An Update of Efficacy and Safety of Cetuximab in Metastatic Colorectal Cancer: A Narrative Review

Advances in Therapy
Giulia FornasierPaolo Baldo

Abstract

Colorectal cancer is the second most common cancer, representing 13% of all diagnosed cancers. Cetuximab is a recombinant chimeric monoclonal IgG1 antibody and epidermal growth factor receptor (EGFR) inhibitor. Cetuximab is approved for the first-line treatment in combination with chemotherapy or as a single agent in patients who have failed or are intolerant to chemotherapy in patients with EGFR-expressing, RAS wild-type metastatic colorectal cancer. Cetuximab efficacy emerged from studies that were conducted to approve the drug. Cetuximab is well tolerated; its toxicities are caused by its mechanism of action and the most common adverse reaction is skin toxicity. The main purpose of this manuscript is to present an update on the evidence-based summary of efficacy and safety and on the cost-effectiveness of cetuximab. Furthermore, it suggests a management of adverse drug reactions to improve the tolerability of the drug.

References

Jul 23, 2004·The New England Journal of Medicine·David CunninghamEric Van Cutsem
Nov 16, 2007·The New England Journal of Medicine·Derek J JonkerMalcolm J Moore
Mar 14, 2008·The New England Journal of Medicine·Christine H ChungThomas A E Platts-Mills
Aug 5, 2008·Critical Reviews in Oncology/hematology·Bruno VincenziGiuseppe Tonini
Oct 24, 2008·The New England Journal of Medicine·Christos S KarapetisJohn R Zalcberg
Apr 3, 2009·The New England Journal of Medicine·Eric Van CutsemPhilippe Rougier
Aug 17, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·K PotthoffA Wollenberg
Jan 29, 2011·The Oncologist·Carmine PintoUNKNOWN European Society of Medical Oncology
Apr 20, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric Van CutsemFortunato Ciardiello
Jun 2, 2011·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Mario E LacoutureUNKNOWN MASCC Skin Toxicity Study Group
Apr 5, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kjell Magne TveitThoralf Christoffersen
Sep 18, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hubert PiessevauxSabine Tejpar
Apr 26, 2014·World Journal of Gastroenterology : WJG·Miguel Jhonatan SoteloEduardo Díaz-Rubio
Jul 25, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E MissiagliaS Tejpar
Aug 15, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M J SorichC S Karapetis
Sep 6, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E Van CutsemUNKNOWN ESMO Guidelines Working Group
Jan 22, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric Van CutsemFortunato Ciardiello
Apr 29, 2015·Nursing & Health Sciences·Ji Young Lim, Wonjung Noh
Jul 5, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D E PetersonUNKNOWN ESMO Guidelines Committee
Oct 19, 2016·Expert Review of Pharmacoeconomics & Outcomes Research·Taehwan ParkDong-Churl Suh
Dec 22, 2016·Oncotarget·Ben ZhaoXianglin Yuan
May 10, 2017·Critical Reviews in Oncology/hematology·Ralf-Dieter HofheinzHans Prenen
Jun 4, 2017·The Oncologist·Emilie M J van BrummelenJan H M Schellens
Jul 1, 2017·JAMA Oncology·Christina Fitzmaurice, Mohsen Naghavi
Sep 9, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S RosellóUNKNOWN ESMO Guidelines Committee
Dec 29, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Theodore M BraskyChi-Ling Chen
Feb 13, 2018·Cancer Discovery·Ryan B CorcoranEric Van Cutsem
Feb 23, 2018·Clinical Drug Investigation·Vladimir M MoiseyenkoEvgeny N Imyanitov
Apr 10, 2018·Gastrointestinal Cancer : Targets and Therapy·Carling UrsemKatherine Van Loon
Jun 2, 2018·Oncoscience·Michael LamTimothy A Yap
Jan 1, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M J SorichC S Karapetis
Jul 1, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S RosellóUNKNOWN ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org

❮ Previous
Next ❯

Citations

Oct 4, 2019·Therapeutic Advances in Medical Oncology·Yuanyuan FuWentong Fang
Aug 3, 2019·Nature Reviews. Gastroenterology & Hepatology·Jordi BruixMaría Reig
Sep 12, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Soehartati A GondhowiardjoAngela Giselvania
Sep 12, 2020·World Journal of Clinical Cases·Jaime González-MonteroLuis Villanueva
Nov 11, 2019·Trends in Pharmacological Sciences·Salvador GuardiolaErnest Giralt
Feb 4, 2021·Bioengineering & Translational Medicine·Daniel C PanSamir Mitragotri
Jul 25, 2021·International Journal of Molecular Sciences·Guido GiordanoMatteo Landriscina
Jul 31, 2021·Molecular Diagnosis & Therapy·Shee Kwan PhungMartin Felices
Oct 21, 2021·American Journal of Physiology. Gastrointestinal and Liver Physiology·María Arredondo-AmadorFermín Sánchez de Medina

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.